H.C. Wainwright analyst Edward White maintained a Hold rating on Clovis Oncology (CLVS – Research Report) today. The company's shares closed last Monday at $0.68, close to its 52-week low of $0.61. According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -29.3% and a 20.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. The word on The Street in general, suggests a Hold analyst consensus rating for Clovis Oncology.
https://www.tipranks.com/news/blurbs/clovis-oncology-clvs-gets-a-hold-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Clovis Oncology Charts.
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Clovis Oncology Charts.